NA
PLX icon

NewEdge Advisors’s Protalix BioTherapeutics PLX Stock Holding History

NewEdge Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,080
Closed -$38.6K – 4122
2025
Q1 		$38.6K Buy
+15,080
New +$36K ﹤0.01% 2639
2023
Q3 		– Sell
-536
Closed -$1.07K – 3609
2023
Q2 		$1.07K Buy
+536
New +$1.28K ﹤0.01% 3236

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

NewEdge Advisors's PLX Position: Q2 2025 in Review

NewEdge Advisors sold out of Protalix BioTherapeutics (PLX) in Q2 2025, closing a stake of 15,080 shares — an estimated $38.6K sold.

NewEdge Advisors first reported a position in PLX in Q2 2023 and held it in 2 quarters. The position peaked at $38.6K in Q1 2025. 63 funds tracked by Wall St. Rank hold PLX as of Q2 2025.

  • NewEdge Advisors reported no remaining Protalix BioTherapeutics position as of Q2 2025 after selling out during the quarter.
  • NewEdge Advisors sold 15,080 Protalix BioTherapeutics shares in Q2 2025, an estimated $38.6K.
  • NewEdge Advisors first reported a position in Protalix BioTherapeutics in Q2 2023 and held it in 2 quarters.
  • NewEdge Advisors's Protalix BioTherapeutics position peaked at $38.6K in Q1 2025.
  • 63 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2025.

Based on NewEdge Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.